IMPLEMENTING DIGITAL TWINS FOR CANCER THERAPY SIMULATION: GENETIC-BASED MEDICAL PERSONALIZATION
Pakistan Pakistan 
Turkey 
Indonesia 
Article Sidebar
-
Artificial Intelligence, Cancer Therapy, Digital Twins
Abstract
Cancer treatment increasingly requires individualized therapeutic strategies because substantial genetic heterogeneity, dynamic tumor evolution, and variable treatment responses limit the effectiveness of standardized clinical protocols. Digital Twin technology has emerged as a promising computational paradigm capable of integrating genomic, physiological, imaging, and clinical data into patient-specific virtual models that support personalized therapeutic planning. This study aimed to evaluate the implementation of Digital Twins for cancer therapy simulation and to examine their contribution to genetic-based medical personalization and clinical decision support. A mixed-methods sequential explanatory design was employed involving 480 patients treated at tertiary oncology centers. Quantitative analyses included descriptive statistics, structural equation modeling, survival analysis, mediation and moderation analyses, whereas qualitative evidence was obtained through semi-structured interviews, clinical observations, multidisciplinary case reviews, and document analysis. Results indicate that Digital Twin technology provides a comprehensive precision oncology framework by integrating computational intelligence, genomic medicine, and real-time clinical information to optimize individualized cancer therapy, improve evidence-based decision-making, and enhance long-term patient outcomes while supporting the broader implementation of personalized medicine.
Full text article
References
Alarcón-Zendejas, A. P. (2022). The promising role of new molecular biomarkers in prostate cancer: From coding and non-coding genes to artificial intelligence approaches. Prostate Cancer and Prostatic Diseases, 25(3), 431–443. https://doi.org/10.1038/s41391-022-00537-2
Aljabali, A. A. A. (2025). Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment. Chemistry and Biodiversity, 22(8). https://doi.org/10.1002/cbdv.202402479
Almansour, N. M. (2022). Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Frontiers in Molecular Biosciences, 9(Query date: 2026-10-14 18:52:52). https://doi.org/10.3389/fmolb.2022.836417
Bera, K. (2022). Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nature Reviews Clinical Oncology, 19(2), 132–146. https://doi.org/10.1038/s41571-021-00560-7
Bilgin, G. B. (2024). Theranostics and artificial intelligence: New frontiers in personalized medicine. Theranostics, 14(6), 2367–2378. https://doi.org/10.7150/thno.94788
Carini, C. (2024). Tribulations and future opportunities for artificial intelligence in precision medicine. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05067-0
Chakraborty, S. (2024). Multi-OMICS approaches in cancer biology: New era in cancer therapy. Biochimica Et Biophysica Acta Molecular Basis of Disease, 1870(5). https://doi.org/10.1016/j.bbadis.2024.167120
Chen, H. (2024). The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Management of subsolid lung nodules. Journal of Thoracic and Cardiovascular Surgery, 168(3), 631–647. https://doi.org/10.1016/j.jtcvs.2024.02.026
Chen, M. (2023). Radiomics and artificial intelligence for precision medicine in lung cancer treatment. Seminars in Cancer Biology, 93(Query date: 2026-10-14 18:52:52), 97–113. https://doi.org/10.1016/j.semcancer.2023.05.004
Chen, Z. (2024). Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01932-y
Danzi, F. (2023). To metabolomics and beyond: A technological portfolio to investigate cancer metabolism. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01380-0
Das, K. P. (2022). Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. Frontiers in Medical Technology, 4(Query date: 2026-10-14 18:52:52). https://doi.org/10.3389/fmedt.2022.1067144
Dey, A. (2023). Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer. Technology in Cancer Research and Treatment, 22(Query date: 2026-10-14 18:52:52). https://doi.org/10.1177/15330338231178403
Dhoundiyal, S. (2024). Radiopharmaceuticals: Navigating the frontier of precision medicine and therapeutic innovation. European Journal of Medical Research, 29(1). https://doi.org/10.1186/s40001-023-01627-0
Dzobo, K. (2022). The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery. Comprehensive Pharmacology, 2(Query date: 2026-10-14 18:52:52), 408–422. https://doi.org/10.1016/B978-0-12-820472-6.00041-4
Esteva, A. (2022). Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. Npj Digital Medicine, 5(1). https://doi.org/10.1038/s41746-022-00613-w
Fan, T. (2023). Therapeutic cancer vaccines: Advancements, challenges, and prospects. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01674-3
Foersch, S. (2023). Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nature Medicine, 29(2), 430–439. https://doi.org/10.1038/s41591-022-02134-1
Gao, Q. (2023). The artificial intelligence and machine learning in lung cancer immunotherapy. Journal of Hematology and Oncology, 16(1). https://doi.org/10.1186/s13045-023-01456-y
Hoffmann, E. (2024). Multiparametric MRI for characterization of the tumour microenvironment. Nature Reviews Clinical Oncology, 21(6), 428–448. https://doi.org/10.1038/s41571-024-00891-1
Huang, Y. (2024). Nanotechnology’s frontier in combatting infectious and inflammatory diseases: Prevention and treatment. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01745-z
Inchingolo, R. (2023). Radiomics in colorectal cancer patients. World Journal of Gastroenterology, 29(19), 2888–2904. https://doi.org/10.3748/wjg.v29.i19.2888
Ivanova, M. (2024). Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Archiv, 484(1), 3–14. https://doi.org/10.1007/s00428-023-03656-w
Khera, R. (2024). Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 84(1), 97–114. https://doi.org/10.1016/j.jacc.2024.05.003
Kim, J. (2024). Strategies for non-viral vectors targeting organs beyond the liver. Nature Nanotechnology, 19(4), 428–447. https://doi.org/10.1038/s41565-023-01563-4
Lin, Z. (2022). Predicting Nanoparticle Delivery to Tumors Using Machine Learning and Artificial Intelligence Approaches. International Journal of Nanomedicine, 17(Query date: 2026-10-14 18:52:52), 1365–1379. https://doi.org/10.2147/IJN.S344208
Liu, Y. (2025). Recent advances in the bench-to-bedside translation of cancer nanomedicines. Acta Pharmaceutica Sinica B, 15(1), 97–122. https://doi.org/10.1016/j.apsb.2024.12.007
Liu, Y. (2026). Spatial omics at the forefront: Emerging technologies, analytical innovations, and clinical applications. Cancer Cell, 44(1), 24–49. https://doi.org/10.1016/j.ccell.2025.12.009
Mi, K. (2024). Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models. Journal of Controlled Release, 374(Query date: 2026-10-14 18:52:52), 219–229. https://doi.org/10.1016/j.jconrel.2024.08.015
Mostafa, G. (2024). The power of deep learning in simplifying feature selection for hepatocellular carcinoma: A review. BMC Medical Informatics and Decision Making, 24(1). https://doi.org/10.1186/s12911-024-02682-1
Osipov, A. (2024). The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Nature Cancer, 5(2), 299–314. https://doi.org/10.1038/s43018-023-00697-7
Sabit, H. (2025). The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities. Cancer Letters, 628(Query date: 2026-10-14 18:52:52). https://doi.org/10.1016/j.canlet.2025.217865
Silva, R. G. L. da. (2024). The advancement of artificial intelligence in biomedical research and health innovation: Challenges and opportunities in emerging economies. Globalization and Health, 20(1). https://doi.org/10.1186/s12992-024-01049-5
Simon, B. D. (2025). The future of multimodal artificial intelligence models for integrating imaging and clinical metadata: A narrative review. Diagnostic and Interventional Radiology, 31(4), 303–312. https://doi.org/10.4274/dir.2024.242631
Sun, S. (2023). Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01606-1
Xia, T. (2024). MRI-Based Radiomics and Deep Learning in Biological Characteristics and Prognosis of Hepatocellular Carcinoma: Opportunities and Challenges. Journal of Magnetic Resonance Imaging, 59(3), 767–783. https://doi.org/10.1002/jmri.28982
